28bio is a biotechnology company focused on bridging the gap between human brain biology and drug development using proprietary neurotechnology. Its platform integrates tissue engineering, neural interfacing, and artificial intelligence to build engineered human brain organoids that mimic memory, learning, and other cognitive functions. The goal is to provide more predictive and human-relevant models to improve the success rates of neurological drug discovery, reducing reliance on traditional animal models.